BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31006094)

  • 1. M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells.
    Gray Z; Tabarraei A; Moradi A; Kalani MR
    Mol Biol Rep; 2019 Jun; 46(3):3371-3379. PubMed ID: 31006094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
    Cary ZD; Willingham MC; Lyles DS
    J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
    Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
    J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix protein of VSV New Jersey serotype containing methionine to arginine substitutions at positions 48 and 51 allows near-normal host cell gene expression.
    Kim GN; Kang CY
    Virology; 2007 Jan; 357(1):41-53. PubMed ID: 16962155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
    Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
    J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
    Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
    Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Vesicular Stomatitis Virus Matrix Protein in Autophagy in the Breast Cancer.
    Askari FS; Mohebbi A; Moradi A; Javid N
    Asian Pac J Cancer Prev; 2021 Jan; 22(1):249-255. PubMed ID: 33507706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell Cycle Arrest in G
    Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
    Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
    Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
    Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors.
    Kim GN; Wu K; Hong JP; Awamleh Z; Kang CY
    J Virol; 2015 Jun; 89(12):6338-51. PubMed ID: 25855732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.
    Ahmed M; Puckett S; Lyles DS
    Cancer Gene Ther; 2010 Dec; 17(12):883-92. PubMed ID: 20725101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity.
    Hoffmann M; Wu YJ; Gerber M; Berger-Rentsch M; Heimrich B; Schwemmle M; Zimmer G
    J Gen Virol; 2010 Nov; 91(Pt 11):2782-93. PubMed ID: 20631091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
    Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
    Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell Death Mechanisms in Esophageal Squamous Cell Carcinoma Induced by Vesicular Stomatitis Virus Matrix Protein.
    Douzandegan Y; Tahamtan A; Gray Z; Nikoo HR; Tabarraei A; Moradi A
    Osong Public Health Res Perspect; 2019 Aug; 10(4):246-252. PubMed ID: 31497497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
    J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.
    Randle RW; Northrup SA; Sirintrapun SJ; Lyles DS; Stewart JH
    Surgery; 2013 Dec; 154(6):1323-29; discussion 1329-30. PubMed ID: 23973113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEBL and AKT1 maybe new targets to eliminate the colorectal cancer cells resistance to oncolytic effect of vesicular stomatitis virus M-protein.
    Mamizadeh Z; Kalani MR; Parsania M; Soltan Dallal MM; Moradi A
    Mol Ther Oncolytics; 2021 Dec; 23():593-601. PubMed ID: 34977336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
    Zhang P; Han X; Tan W; Chen D; Sun Q
    Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular stomatitis virus as a treatment for colorectal cancer.
    Stewart JH; Ahmed M; Northrup SA; Willingham M; Lyles DS
    Cancer Gene Ther; 2011 Dec; 18(12):837-49. PubMed ID: 21886191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.